Chandraprabhu Jangme

Chandraprabhu Jangme

Auto-generated profile, based on publicly available information

Chandraprabhu Jangme

Department of Pharmaceutics, D.Y. Patil Education Society, Kolhapur, Maharashtra India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2026 in Drug Delivery Letters
Verified
Journal Article
Closed access
PDF file
ATAshok Thulluru
Ashok Thulluru
CJChandraprabhu Jangme
Chandraprabhu Jangme
RVRohini Vichare
Rohini Vichare
SDShraddha Dingare Deshpande
Shraddha Dingare Deshpande
VPVrushabh Patil
Vrushabh Patil
Introduction: Obesity affects hundreds of millions of adults worldwide and represents a major risk factor for metabolic disorders, including type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. Berberine (BBR) and epigallocatechin gallate (EGCG) are bioactive phytochemicals that exhibit anti-obesity effects through multiple mechanisms, including activation of AMP-activated protein kinase (AMPK), inhibition of lipogenesis, stimulation of thermogenesis, and modulation of the gut microbiota. However, their therapeutic applications are limited by poor oral bioavailability due to low aqueous solubility, chemical instability, and extensive first-pass metabolism, which restrict their absorption and biological efficacy. Methods: A comprehensive literature analysis was conducted on novel nanocarrier platforms, including lipid-based systems (liposomes, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions), polymeric nanoparticles (PLGA, chitosan, protein-based carriers), inorganic nanocarriers, and molecular complexation strategies for BBR and EGCG delivery in obesity models. Results: Recent studies indicate that nano-formulation strategies can substantially enhance the solubility, stability, absorption, and bioavailability of BBR and EGCG compared with conventional formulations. Different nanocarrier systems demonstrate distinct advantages; however, limitations related to formulation stability, scalability, safety assessment, reproducibility, and regulatory approval remain major barriers to clinical application. Preclinical studies suggest that nano-delivered BBR and EGCG may improve metabolic outcomes, including reductions in body weight gain, adiposity, inflammation, and hepatic lipid accumulation, although further validation in well-designed clinical studies is required. Discussion: This review systematically evaluates advanced nano-delivery systems designed to overcome bioavailability barriers of BBR and EGCG, focusing on pharmacokinetic enhancement, targeted delivery, and improved anti-obesity efficacy across preclinical models to inform clinical translation strategies. Conclusion: Nanomedicine-based delivery platforms represent a promising strategy to unlock the anti-obesity therapeutic potential of BBR and EGCG. Future research should focus on the co-delivery of Nanoformulations that utilise the complementary anti-obesity effects of BBR and EGCG and evaluate their clinical feasibility.

29 September 2026 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SKSundeep Kadasi
Sundeep Kadasi
AKAishwarya Avinash Kholkumbe
Aishwarya Avinash Kholkumbe
CJChandraprabhu Jangme
Chandraprabhu Jangme
VPVrushabh Sunil Patil
Vrushabh Sunil Patil
RARameshwar Ardad
Rameshwar Ardad
SHShweta Omkar Hodage
Shweta Omkar Hodage
Introduction/Objective:: Multidrug Resistance (MDR) remains a major obstacle to effective cancer chemotherapy, driven by multiple interconnected mechanisms, including overexpression of ATP-binding Cassette (ABC) transporters, enhanced DNA repair, apoptosis evasion, and protumorigenic microenvironmental factors. Heat Shock Protein 90 (HSP90) has emerged as a master regulator of MDR by chaperoning multiple client proteins involved in drug efflux, survival signaling pathways, and cellular stress responses. These mechanisms collectively decrease intracellular drug accumulation and promote tumor cell survival, leading to therapeutic failure. This review aims to summarize HSP90-targeted therapeutic strategies for overcoming MDR in cancer and evaluate their mechanistic basis, efficacy, and translational potential. Methods:: A systematic literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar up to 2010-2026. Keywords included “HSP90,” “multidrug resistance,” “cancer,” “HSP90 inhibitors,” “prodrug,” “ADC,” and “nanotechnology,” combined using Boolean operators. Relevant preclinical and clinical studies on HSP90-targeted strategies to overcome MDR were included, while duplicates and studies that were irrelevant or insufficiently detailed were excluded. Eligible studies were screened and analyzed for mechanisms, therapeutic outcomes, and limitations. Results:: Small-molecule HSP90 inhibitors, including geldanamycin derivatives and resorcinol-based compounds, demonstrate potential in destabilizing MDR-associated client proteins such as P-glycoprotein, MRP1, BCRP, and survival kinases, thereby restoring sensitivity of resistant cancer cells to chemotherapy. Prodrug strategies improve bioavailability and reduce systemic toxicity while preserving HSP90 inhibitory activity. Hybrid molecules that integrate HSP90 inhibition with complementary mechanisms, such as HDAC inhibition and kinase inhibition, provide synergistic multi-targeted effects against resistance pathways. Antibody–drug conjugates facilitate tumor-selective delivery of HSP90 inhibitors, enabling receptormediated internalization and reducing the impact of efflux mechanisms. Furthermore, nanotechnology-based delivery platforms, including liposomes, polymeric nanoparticles, and stimuli-responsive carriers, enhance pharmacokinetics, enable co-delivery of HSP90 inhibitors with chemotherapeutic agents, and support controlled intratumoral drug release. Discussion:: HSP90-targeted strategies represent a promising approach for reversing MDR by simultaneously regulating multiple resistance-associated pathways. The ability of HSP90 inhibitors to disrupt drug efflux transporters, survival signaling networks, and stress adaptation mechanisms provides a strong rationale for their integration with conventional chemotherapy and emerging targeted therapies. However, clinical translation remains challenging due to tumor heterogeneity, biological barriers, dose-limiting toxicities, and variations in patient response. Rational combination strategies, biomarker-guided patient selection, and advanced delivery technologies are essential to maximize therapeutic benefits and improve clinical outcomes. Conclusion:: HSP90-targeted therapeutic approaches offer significant potential for overcoming MDR in cancer by restoring drug sensitivity and enhancing treatment efficacy. Future progress will depend on optimized combination therapies incorporating MDR modulators, personalized treatment strategies guided by predictive biomarkers, and innovative technologies such as artificial intelligence-assisted drug design and CRISPR-based gene editing. Continued interdisciplinary research is required to translate HSP90- targeted innovations into effective clinical interventions for patients with drug-resistant cancers.

16 September 2026 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
PDF file
ATAshok Thulluru
Ashok Thulluru
CJChandraprabhu Jangme
Chandraprabhu Jangme
VPVrushabh Patil
Vrushabh Patil
Introduction/ Objective: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial joints, leading to joint destruction and systemic complications. Existing therapies, such as Disease-Modifying Antirheumatic Drugs (DMARDs) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), are typically associated with low efficiency, systemic side effects, and poor patient compliance. Methods: A literature search was conducted using PubMed, Google Scholar, ScienceDirect, and Web of Science to identify relevant studies published between 2005 and 2025. The search employed the keywords "rheumatoid arthritis," "cubosomes," "cubosomal gel," "nanocarriers," and "targeted drug delivery" with Boolean operators (AND/OR). English-language studies focusing on cubosome-based drug delivery for rheumatoid arthritis were included, while non-English publications, duplicates, and unrelated studies were excluded. The selected literature was qualitatively synthesized to summarize current advances and therapeutic potential. Results: Preclinical research demonstrates that cubosomal gels enhance Pharmacodynamic effects, improve drug retention in inflamed joints, and reduce systemic toxicity. Such systems show improved bioavailability and therapeutic action compared to traditional therapies. Nonetheless, issues such as scale-up manufacturing, stability, and regulatory acceptance remain. Discussions: Cubosomal gels would be an effective platform for safer, more effective, and personalized RA therapies. New studies are advised on stimuli-responsive systems and multifunctional targeting to maximize clinical responses and translate them into patient care. Conclusion: Nanocarrier-based drug delivery systems offer enhanced targeted delivery and controlled release. Cubosomes, lipid-based nanostructures with bicontinuous cubic phases, effectively encapsulate both hydrophilic and hydrophobic drugs. This study demonstrates that cubosomes significantly improve topical RA treatment when incorporated into gel formulations, enhancing skin penetration, bioadhesion, and localized drug delivery. These findings have important clinical implications, suggesting cubosomes may reduce systemic side effects while maximizing therapeutic efficacy at diseased sites.

5 October 2026 in Progress in Nanoscience and Nanotechnology
Verified
Journal Article
Closed access
PDF file
SPShubham Patil
Shubham Patil
CJChandraprabhu Jangme
Chandraprabhu Jangme
VPVrushabh Patil
Vrushabh Patil
Introduction: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by inflammation and joint tissue damage. Traditional topical and transdermal treatments often struggle with low skin penetration, delivering only small amounts of the drug to inflamed joints. To address this, researchers have explored using Transethosome, a new type of ultra-deformable vesicle nanocarrier, as a potential method to improve dermal drug delivery in RA. Methods: A systematic literature review was conducted to assess recent advances in transethosomebased nanocarriers for topical and transdermal drug delivery, with particular emphasis on rheumatoid arthritis. PubMed, Scopus, and Web of Science were searched using predefined keywords and Boolean operators. Peer-reviewed original studies reporting relevant preclinical or comparative findings were included, whereas reviews and studies lacking quantitative data were excluded. Articles were screened by title, abstract, and full text, and relevant data on formulation, preparation, characterization, encapsulation efficiency, skin permeation, drug retention, therapeutic efficacy, and safety were extracted. Results: Transethosome-based formulations showed superior skin permeation and drug retention in joint tissues compared to conventional gels, liposomes, ethosomes, and transferosomes. Preclinical studies indicated reduced joint swelling, decreased inflammatory cytokine levels, improved histopathology, and low toxicity of the system. Discussion: The evidence suggests that Transethosome is a patient-friendly targeted and sustained therapy method for RA. However, issues related to formulation stability, large-scale production, and clinical application remain. Further optimization of formulations and research on combination therapies are necessary to enhance therapeutic outcomes. Conclusion: Transethosome-based nanocarriers demonstrate significant potential as a targeted dermal delivery system for rheumatoid arthritis treatment. Preclinical evidence indicates superior skin penetration, enhanced drug retention at inflamed joints, and reduced systemic toxicity compared to conventional delivery systems. However, substantial challenges remain in formulation stability, scale-up manufacturing, regulatory compliance, and clinical translation. Future research should focus on optimizing formulation parameters, conducting in vivo efficacy and safety studies, establishing dose-response relationships, and exploring combination therapies with existing diseasemodifying antirheumatic drugs.

29 September 2026 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ATAshok Thulluru
Ashok Thulluru
VPVrushabh Patil
Vrushabh Patil
CJChandrapraphu Jangme
Chandrapraphu Jangme
PCPoonam Chougule
Poonam Chougule
PPPrajakta Pujari
Prajakta Pujari
Introduction: Drug-Induced Liver Injury (DILI) is a leading cause of drug attrition, postmarketing withdrawals, and acute liver failure. It presents a major barrier to the safe development of new therapeutics, particularly due to its unpredictable pathogenesis and the lack of reliable preclinical models. Current diagnostic tools, primarily reliant on liver enzyme elevations, lack specificity and sensitivity, especially in cases of idiosyncratic DILI. With increasing awareness of these limitations, there is growing interest in integrating advanced delivery systems, predictive models, and pharmacogenomic screening into drug safety assessment. Methodology: This review systematically synthesizes peer-reviewed literature identified through Scopus, PubMed, and Web of Science, published over the past two decades. The review focuses on mechanistic insights into Drug-Induced Liver Injury (DILI), diagnostic challenges, and recent advances in nanocarrier-based drug delivery and predictive strategies. Relevant literature was identified using search terms such as “DILI,” “nanocarriers,” “pharmacogenomics,” and “liver toxicity. Results: Recent findings underline the complex etiology of DILI, involving mitochondrial dysfunction, reactive metabolite accumulation, and immune-mediated responses. Nanoparticle-based drug formulations, including liposomes, polymeric nanoparticles, and dendritic systems, demonstrate promise in reducing hepatic exposure and delivering hepatoprotective co-agents. Innovations such as liver-on-a-chip models and AI-driven predictive tools offer enhanced screening potential. Pharmacogenomic profiling is increasingly recognized for enabling individualized risk assessment. Discussion: The integration of nanotechnology with predictive toxicology and pharmacogenomics represents a significant advancement in DILI prevention and early detection. These emerging approaches address many limitations of conventional preclinical models by providing more physiologically relevant systems and supporting personalized therapeutic strategies. However, challenges related to clinical translation, regulatory acceptance, cost, and validation across diverse populations remain to be addressed. Conclusion: Advances in nanocarrier-based drug delivery, pharmacogenomics, and human-relevant predictive models have the potential to transform DILI risk assessment and improve drug safety. Continued interdisciplinary research, large-scale clinical validation, and regulatory integration are essential for translating these innovations into routine pharmaceutical development and clinical practice.